The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2

Br J Haematol. 2022 Jan;196(2):362-367. doi: 10.1111/bjh.17821. Epub 2021 Sep 6.
No abstract available

Keywords: BNT162b2; haematological cancers; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Publication types

  • Letter

MeSH terms

  • Aged
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / blood*
  • BNT162 Vaccine / immunology*
  • COVID-19 / prevention & control*
  • Cohort Studies
  • Female
  • Hematologic Neoplasms / immunology
  • Humans
  • Immunogenicity, Vaccine
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / blood*
  • Kinetics
  • Leukemia / immunology
  • Lymphoma, Non-Hodgkin / immunology
  • Male
  • Middle Aged
  • Multiple Myeloma / immunology
  • Myeloproliferative Disorders / immunology
  • SARS-CoV-2 / immunology*
  • Time Factors
  • Vaccination

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G
  • BNT162 Vaccine